Hypertensive heart failure in nigerian africans: Insights from the abeokuta heart failure registry

Journal of Clinical Hypertension

Volumn 17, Issue 4, 2015, Pages 263-272

  Ogah, Okechukwu S ^a,b   Sliwa, Karen ^b,c   Akinyemi, Joshua O ^d   Falase, Ayodele O ^a   Stewart, Simon ^e  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF IBADAN   (Nigeria)

^e AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; HYDRALAZINE; ISOSORBIDE; LOOP DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; AFRICAN; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; NIGERIAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; AGED; BLACK PERSON; ETHNOLOGY; HOSPITAL MORTALITY; LENGTH OF STAY; MIDDLE AGED; NIGERIA; PROGNOSIS; REGISTER; RISK FACTOR; STATISTICAL MODEL; SURVIVAL ANALYSIS;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYPERTENSION; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; NIGERIA; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84926164901     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12496     Document Type: Article

References (49)

1. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377:568-577.
2. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
4. Modesti PA, Agostoni P, Agyemang C, et al. Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. J Hypertens. 2014;32:951-960.
5. Ogah OS, Okpechi I, Chukwuonye II, et al. Blood pressure, prevalence of hypertension and hypertension related complications in Nigerian Africans: a review. World J Cardiol. 2012;4:327-340.
6. Ogah OS. Hypertension in sub-Saharan African populations: the burden of hypertension in Nigeria. Ethn Dis. 2006;16:765.
7. Ojji DB, Alfa J, Ajayi SO, et al. Pattern of heart failure in Abuja, Nigeria: an echocardiographic study. Cardiovasc J Afr. 2009;20:349-352.
8. Ojji D, Stewart S, Ajayi S, et al. A predominance of hypertensive heart failure in the Abuja Heart Study cohort of urban Nigerians: a prospective clinical registry of 1515 de novo cases. Eur J Heart Fail. 2013;15:835-842.
9. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012;172:1386-1394.
10. Ogah OS, Stewart S, Falase AO, et al. Contemporary profile of acute heart failure in Southern Nigeria: data from the Abeokuta heart failure clinical registry. JACC Heart Fail. 2014;2:250-259.
11. The Global Standardized Hypertension Treatment Project. Centers for Diseases Control and Prevention 2014. http://www.cdc.gov/globalhealth/ncd/hypertension-treatment.htm. Accessed November 3, 2014.
12. National Population Census. Abuja: National Population Commission; 2006.
13. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446.
14. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933-989.
15. Rickham PP. Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. Br Med J. 1964;2:177.
16. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. American Society of Hypertension. Am J Hypertens. 1992;5:207-209.
17. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (The JNC 7 Report). JAMA. 2003;289:2560-2572.
18. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27:2725-2736.
19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
20. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161-186.
21. Casale PN, Devereux RB, Alonso DR, et al. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75:565-572.
22. Okin PM, Devereux RB, Nieminen MS, et al. Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point. J Am Coll Cardiol. 2001;38:514-520.
23. Ogah OS, Adebiyi AA, Oladapo OO, et al. Association between electrocardiographic left ventricular hypertrophy with strain pattern and left ventricular structure and function. Cardiology. 2006;106:14-21.
24. Lester SJ, Ryan EW, Schiller NB, Foster E. Best method in clinical practice and in research studies to determine left atrial size. Am J Cardiol. 1999;84:829-832.
25. Thomas L, Levett K, Boyd A, et al. Compensatory changes in atrial volumes with normal aging: is atrial enlargement inevitable? J Am Coll Cardiol. 2002;40:1630-1635.
26. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
27. Reichek N. Two-dimensional echocardiography for determination of left ventricular mass. Am J Card Imaging. 1994;8:305-309.
28. Palmieri V, Dahlof B, De QV, et al. Reliability of echocardiographic assessment of left ventricular structure and function. The PRESERVE study. J Am Coll Cardiol. 1999;34:1625-1632.
29. De Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
30. De Simone G, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25:1056-1062.
31. Nunez E, Arnett DK, Benjamin EJ, et al. Optimal threshold value for left ventricular hypertrophy in blacks: the Atherosclerosis Risk in Communities study. Hypertension. 2005;45:58-63.
32. Adebiyi AA, Ogah OS, Aje A, et al. Echocardiographic partition values and prevalence of left ventricular hypertrophy in hypertensive Nigerians. BMC Med Imaging. 2006;6:10.
33. Roman MJ, Pickering TG, Schwartz JE, et al. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol. 1995;25:83-90.
34. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
35. Ogah OS, Adebanjo AT, Otukoya AS, Jagusa TJ. Echocardiography in Nigeria: use, problems, reproducibility and potentials. Cardiovasc Ultrasound. 2006;4:13.
36. Dzudie A, Kengne AP, Mbahe S, et al. Chronic heart failure, selected risk factors and co-morbidities among adults treated for hypertension in a cardiac referral hospital in Cameroon. Eur J Heart Fail. 2008;10:367-372.
37. Stewart S, Wilkinson D, Hansen C, et al. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation. 2008;118:2360-2367.
38. Sato N, Kajimoto K, Asai K, et al. Acute Decompensated Heart Failure Syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J. 2010;159:949-955, e1.
39. Nieminen MS, Harjola VP, Hochadel M, et al. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail. 2008;10:140-148.
40. Ogun SA, Ojini FI, Ogungbo B, et al. Stroke in south west Nigeria: a 10-year review. Stroke. 2005;36:1120-1122.
41. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurology. 2007;6:182-187.
42. Seck SM, Diallo IM, Diagne SI. Epidemiological patterns of chronic kidney disease in black African elders: a retrospective study in West Africa. Saudi J Kidney Dis Transpl. 2013;24:1068-1072.
43. Ulasi II, Ijoma CK. The enormity of chronic kidney disease in Nigeria: the situation in a teaching hospital in South-East Nigeria. J Trop Med. 2010;2010:501957.
44. Sindhu S, Pholpet C, Puttapitukpol S. Meeting the challenges of chronic illness: a nurse-led collaborative community care program in Thailand. Collegian. 2010;17:93-99.
45. Levitt NS, Steyn K, Dave J, Bradshaw D. Chronic noncommunicable diseases and HIV-AIDS on a collision course: relevance for health care delivery, particularly in low-resource settings-insights from South Africa. Am J Clin Nutr. 2011;94:1690S-1696S.
46. Foodstuffs, cosmetics and disinfectants Act, 1972 (Act 54 of 1972) Department of Health, Republic of South Africa, 2012. http://www.doh.gov.za/docs/foodcontrol/comments/2012/fcr533.pdf. Accessed April 6, 2013.
47. Gaziano TA, Young CR, Fitzmaurice G, et al. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet. 2008;371:923-931.
48. Verdecchia P, Schillaci G, Reboldi G, et al. Prognostic value of midwall shortening fraction and its relation with left ventricular mass in systemic hypertension. Am J Cardiol. 2001;87:479-482, A7.
49. Wachtell K, Gerdts E, Palmieri V, et al. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention for Endpoint reduction study. J Hypertens. 2010;28:1541-1546.